Phaseline

Companies › XYone Therapeutics

XYone Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XYA02–Phase 1MUC1-expressing Advanced, Relapsed and/or Refractory Solid TumorsSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07670312XYA02Phase 1MUC1-expressing Advanced, Relapsed and/or Refractory Solid TumorsOncologySep 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.